Raptor Falls On Failed Investigator-Run NASH Study
This article was originally published in Scrip
Executive Summary
Raptor Pharmaceuticals fell 37.5% on Sept. 14 to $7.52 per share after the Novato, California-based company revealed that RP103, a delayed-release version of its approved cystinosis drug Procysbi (cysteamine bitartrate) failed in a Phase IIb pediatric non-alcoholic steatohepatitis (NASH) clinical trial.
You may also be interested in...
Raptor Buy Bolsters Horizon's Orphan Business As Primary Care Foots The Bill
Horizon will boost its orphan drug business through the acquisition of Raptor, using a combination of debt and cash from its primary care and other assets to fund the transaction.
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.
Finance Watch: Another Bevy Of VC Mega-Rounds, Including $175m For Capstan
Private Company Edition: Capstan and Engrail raised $175m and $157m, respectively, in series B venture capital rounds in addition to Madrigal’s $400m-plus launch and Clasp’s $150m series A.